MDS research criteria for prodromal Parkinson's disease

Daniela Berg, Ronald B. Postuma, Charles Howard Adler, Bastiaan R. Bloem, Piu Chan, Bruno Dubois, Thomas Gasser, Christopher G. Goetz, Glenda Halliday, Lawrence Joseph, Anthony E. Lang, Inga Liepelt-Scarfone, Irene Litvan, Kenneth Marek, José Obeso, Wolfgang Oertel, C. Warren Olanow, Werner Poewe, Matthew Stern, Günther Deuschl

Research output: Contribution to journalArticle

387 Citations (Scopus)

Abstract

This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.

Original languageEnglish (US)
Pages (from-to)1600-1611
Number of pages12
JournalMovement Disorders
Volume30
Issue number12
DOIs
StatePublished - Oct 1 2015

Fingerprint

Parkinson Disease
Research
Signs and Symptoms
Parkinsonian Disorders
Routine Diagnostic Tests
Therapeutics

Keywords

  • Diagnosis
  • Parkinson's disease
  • Prodromal

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., ... Deuschl, G. (2015). MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 30(12), 1600-1611. https://doi.org/10.1002/mds.26431

MDS research criteria for prodromal Parkinson's disease. / Berg, Daniela; Postuma, Ronald B.; Adler, Charles Howard; Bloem, Bastiaan R.; Chan, Piu; Dubois, Bruno; Gasser, Thomas; Goetz, Christopher G.; Halliday, Glenda; Joseph, Lawrence; Lang, Anthony E.; Liepelt-Scarfone, Inga; Litvan, Irene; Marek, Kenneth; Obeso, José; Oertel, Wolfgang; Olanow, C. Warren; Poewe, Werner; Stern, Matthew; Deuschl, Günther.

In: Movement Disorders, Vol. 30, No. 12, 01.10.2015, p. 1600-1611.

Research output: Contribution to journalArticle

Berg, D, Postuma, RB, Adler, CH, Bloem, BR, Chan, P, Dubois, B, Gasser, T, Goetz, CG, Halliday, G, Joseph, L, Lang, AE, Liepelt-Scarfone, I, Litvan, I, Marek, K, Obeso, J, Oertel, W, Olanow, CW, Poewe, W, Stern, M & Deuschl, G 2015, 'MDS research criteria for prodromal Parkinson's disease', Movement Disorders, vol. 30, no. 12, pp. 1600-1611. https://doi.org/10.1002/mds.26431
Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B et al. MDS research criteria for prodromal Parkinson's disease. Movement Disorders. 2015 Oct 1;30(12):1600-1611. https://doi.org/10.1002/mds.26431
Berg, Daniela ; Postuma, Ronald B. ; Adler, Charles Howard ; Bloem, Bastiaan R. ; Chan, Piu ; Dubois, Bruno ; Gasser, Thomas ; Goetz, Christopher G. ; Halliday, Glenda ; Joseph, Lawrence ; Lang, Anthony E. ; Liepelt-Scarfone, Inga ; Litvan, Irene ; Marek, Kenneth ; Obeso, José ; Oertel, Wolfgang ; Olanow, C. Warren ; Poewe, Werner ; Stern, Matthew ; Deuschl, Günther. / MDS research criteria for prodromal Parkinson's disease. In: Movement Disorders. 2015 ; Vol. 30, No. 12. pp. 1600-1611.
@article{432160ec6383474680350303f86a84ac,
title = "MDS research criteria for prodromal Parkinson's disease",
abstract = "This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80{\%} certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian na{\"i}ve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.",
keywords = "Diagnosis, Parkinson's disease, Prodromal",
author = "Daniela Berg and Postuma, {Ronald B.} and Adler, {Charles Howard} and Bloem, {Bastiaan R.} and Piu Chan and Bruno Dubois and Thomas Gasser and Goetz, {Christopher G.} and Glenda Halliday and Lawrence Joseph and Lang, {Anthony E.} and Inga Liepelt-Scarfone and Irene Litvan and Kenneth Marek and Jos{\'e} Obeso and Wolfgang Oertel and Olanow, {C. Warren} and Werner Poewe and Matthew Stern and G{\"u}nther Deuschl",
year = "2015",
month = "10",
day = "1",
doi = "10.1002/mds.26431",
language = "English (US)",
volume = "30",
pages = "1600--1611",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - MDS research criteria for prodromal Parkinson's disease

AU - Berg, Daniela

AU - Postuma, Ronald B.

AU - Adler, Charles Howard

AU - Bloem, Bastiaan R.

AU - Chan, Piu

AU - Dubois, Bruno

AU - Gasser, Thomas

AU - Goetz, Christopher G.

AU - Halliday, Glenda

AU - Joseph, Lawrence

AU - Lang, Anthony E.

AU - Liepelt-Scarfone, Inga

AU - Litvan, Irene

AU - Marek, Kenneth

AU - Obeso, José

AU - Oertel, Wolfgang

AU - Olanow, C. Warren

AU - Poewe, Werner

AU - Stern, Matthew

AU - Deuschl, Günther

PY - 2015/10/1

Y1 - 2015/10/1

N2 - This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.

AB - This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.

KW - Diagnosis

KW - Parkinson's disease

KW - Prodromal

UR - http://www.scopus.com/inward/record.url?scp=84944460691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944460691&partnerID=8YFLogxK

U2 - 10.1002/mds.26431

DO - 10.1002/mds.26431

M3 - Article

C2 - 26474317

AN - SCOPUS:84944460691

VL - 30

SP - 1600

EP - 1611

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 12

ER -